New data on combination treatments for melanoma
Monday, September 29, 2014 - 09:51
in Health & Medicine
Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data.